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ABSTRACT | About 70% of cases of kidney cancer are localized or locally advanced at 
diagnosis. Among patients who undergo surgery for these cancers, 30–35% will 
eventually develop potentially fatal metachronous distant metastases. Effective 
adjuvant treatments are urgently needed to reduce the risk of recurrence of kidney 
cancer and of dying of metastatic disease. To date, almost all of the tested adjuvant 
agents have failed to demonstrate any benefit. Only two trials of an autologous renal 
tumour cell vaccine and of the VEGFR tyrosine kinase inhibitor sunitinib have shown 
positive results but these have been criticized for methodological reasons and 
conflicting data, respectively. The results of two additional trials of targeted agents as 
adjuvant therapies have not yet been published. Novel immune checkpoint inhibitors 
are promising approaches to adjuvant therapy in kidney cancer and a number of trials 
are now underway. An important component of the management of patients with 
kidney cancer, particularly those who undergo radical resection for localized renal cell 
carcinoma, is the preservation of kidney function to reduce morbidity and mortality. 
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The optimal management of these patients therefore requires a multidisciplinary 
approach involving nephrologists, oncologists, urologists and pathologists.  
 
INTRODUCTION 
Estimates suggest that kidney cancer is the twelfth most common cancer worldwide, 
with 338,000 new cases diagnosed in 20121. In 2017, around 63,990 new cases of 
kidney cancer (40,610 in men and 23,380 in women) and 14,400 deaths owing to 
kidney cancer (9,470 in men and 4,930 in women) were estimated to occur in the US2. 
About 70% of cases of kidney cancer are localized or locally advanced at diagnosis and 
thus are potentially curable by means of surgical resection alone3. However, 30–35% 
of patients who are resected for a localized or locally advanced kidney tumour will 
eventually develop metachronous distant metastases4, which may occur even 
decades after resection of the primary tumor and can ultimately lead to death. Data 
from the US National Cancer Database indicate that although the observed 5-year 
cancer-specific survival of TNM (tumour, node, metastases) stage I and II kidney 
cancers (Box 1) are 81% and 74% respectively, the observed 5-year survival of patients 
with stage III kidney cancers falls dramatically to 53%5, mainly owing to the 
development of distant metastases. Effective adjuvant treatments are essential to 
reduce the risk of recurrence and associated mortality, especially in high-risk patients. 
For decades, the adjuvant treatment of radically resected kidney cancer has 
remained a ‘black hole’ of medical oncology as almost all of the tested agents have 
failed to demonstrate a benefit6. Despite the significant improvement in survival 
achieved with the use of vascular endothelial growth factor receptor (VEGFR)–
tyrosine kinase inhibitors (TKIs) in the metastatic setting7, randomized controlled trials 
(RCTs) of these agents as adjuvant therapies have yielded conflicting results. 
In this Review, we discuss the issue of defining the risk of relapse of kidney 
cancer and comment on the results of trials of early adjuvant therapies and VEGFR-
TKIs. We also discuss the potential of immune checkpoint inhibitors as adjuvant 
therapies and highlight the need for true multidisciplinary management of patients 
with radically resected kidney cancer. 
 
EVALUATING THE RISK OF RELAPSE 
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The identification of patients who are at increased risk of relapse is key in order to 
develop rational adjuvant strategies. A number of predictive models have been 
developed to accomplish this goal. These models all incorporate widely available, 
easily obtainable, clinicopathologic variables that are associated with prognosis 
following surgery. The two most commonly used models, which are utilized in the 
present generation of adjuvant trials, are the UCLA Integrated Scoring System (UISS)8 
and the Leibovich score9. 
The UISS includes two tumor-specific features – the TNM stage and Fuhrman 
grade (a pathology classification based on nuclear characteristics) – together with a 
patient-specific feature such as the Eastern Cooperative Oncology Group (ECOG) 
performance status8. This combination of these features stratifies patients into low, 
intermediate and high-risk prognostic categories. In patients with non-metastatic 
disease, the application of the UISS system correctly predicted 2 year and 5-year 
survival rates irrespective of tumor histology in 76.5-86.3% of patients8. The UISS is 
also prognostic in the metastatic setting.  
In 2003, Leibovich and colleagues identified 5 features in patients with clear 
cell renal cell carcinoma (ccRCC) — tumor stage, regional lymph node status, tumor 
size, nuclear grade, and histologic tumor necrosis — that were significantly associated 
with progression to metastatic RCC9. When used in combination, these features were 
able to differentiate between patients at higher and lower risk of dying of metastatic 
disease, with a predictive accuracy of >80%. The UISS and Leibovich models were both 
externally validated but the Leibovich model has been shown to be superior in terms 
of predictive accuracy10. These models and others such as the SSIGN11, Karakiewicz12 
and Kattan13 models (Table 1) serve as adjunctive tools for patient counseling but do 
not provide clear guidance on when to use adjuvant therapy. Furthermore, different 
prognostic systems may yield very different risk estimates14. For example, the 5-year 
disease-free survival (DFS) estimate for a patient with primary TNM stage T2, N0 
disease (Fuhrman grade 2) would be 85.4% according to the Leibovich model but only 
66% according to the the Kattan nomogram13. Conversely, a patient with pT3, N0 
disease (Fuhrman grade 3) would have a 5-year DFS estimate of only 50% using the 
Leibovich model versus 74% using the Kattan nomogram13. 
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Unfortunately, prognostic systems based on clinicopathologic variables are not 
able to capture the biology of the tumor, resulting in a substantial bias that the 
application of gene expression technologies to tumor characterization is trying to 
overcome. ClearCode34 is a 34-gene expression panel that can be used to classify 
ccRCC into two subtypes, clear cell A (ccA) and clear cell B (ccB), that are significantly 
associated with relapse-free survival (RFS), cancer-specific survival (CSS) and overall 
survival (OS)15,16. In a cohort of 265 patients with ccRCC, the predictive accuracy of 
ClearCode34 was found to be superior to that of other prognostic scores (including 
the UISS score) in predicting death and recurrence15. 
A separate 16-gene expression panel was used to build a scoring system that 
can predict recurrence after surgery in stage I-III ccRCC17. This score, which was 
validated in an independent French cohort of 626 patients, was significantly 
associated with recurrence following surgery for localized disease17. In multivariable 
analyses, the recurrence score was significantly associated with the risk of tumour 
recurrence after stratification by stage and adjustment for tumour size, grade or 
Leibovich score. This score was able to identify a clinically significant number of high-
risk patients with stage I disease as well as low-risk patients with more advanced 
disease (stage II and III)17. 
Another study identified mutation-defined subtypes of ccRCC with distinct 
clinical outcomes: a high-risk BAP1-mutant group and a lower risk PBRM1-mutant 
group18. Notably, 80% of patients in the development and validation cohorts had 
localized (or loco-regional) disease; therefore the population in this study was fairly 
similar to that of the recurrence score study described above. 
Although a molecular gene-expression model would be ideal for the 
stratification of radically resected patients in clinical trials, none of the available scores 
are ready for widespread everyday clinical use owing to the expertise needed, the 
associated costs and the unresolved discrepancies between the different sets of genes 
found to be prognostic in the different scores. In our opinion, the Leibovich score is 
currently the best model for predicting risk of relapse in everyday clinical practice. 
 
EARLY ADJUVANT TRIALS 
Before the era of VEGFR-TKIs, trials of adjuvant treatments including radiotherapy19, 
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cytokines (with or without chemotherapy)20-25, vaccines26-29, single-agent 
chemotherapy and other agents such as medroxyprogesterone acetate, thalidomide 
and girentuximab30-33, yielded no benefits in terms of disease-free survival (DFS) 
and/or overall survival, with the exception of a trial of an autologous renal tumour cell 
vaccine that was published in 200428 (Supplementary table 1). In our opinion, four of 
these early adjuvant trials20,28,29,33, including the tumour cell vaccine trial28, warrant 
further discussion (Table 2). 
In 2001, a RCT tested the hypothesis that 6-months of adjuvant therapy with 
interferon- (IFN) could improve overall and event-free survival (EFS) in patients with 
radically resected Robson stage II kidney cancer (i.e. a tumor invading perinephric fat 
but not extended beyond Gerota’s fascia) or Robson stage III kidney cancer (i.e. a 
tumor invading the renal vein or inferior vena cava and/or spreading to regional lymph 
nodes)20. Notably, the study protocol recommended unilateral para-aortic lymph 
node dissection and the researchers relied on the pathologic report to verify that 
lymphadenectomy was performed. The overall survival probability at 5 years after 
surgery was 0.665 for the control group and 0.660 for the treated group; this 
difference was not statistically significant (P = 0.861; Hazard Ratio [HR], IFN vs control 
1.040, 95% confidence interval (95% CI) 0.671–1.613). The corresponding EFS 
probabilities (0.671 and 0.567, respectively) also did not differ significantly between 
the study groups (P = 0.107; HR IFN versus control = 1.412, 95% CI 0.927–2.149) 18.  
A subgroup analysis of this RCT reported no significant difference in the 
cumulative probability of death among patients in the treated versus control groups 
with pN0 (0.16 versus 0.10) and pN1 tumours (0.25 versus 0.25)20. Among patients 
with pN2 or pN3 tumours, the observed difference in probability of death between 
the treatment and control groups clearly and significantly favoured the treated 
patients (0.39 for IFN versus 0.92 for control). This observation has no practical 
relevance because of the extremely low number of patients with pN2 or pN3 tumours 
included in the study (n = 13 in each study group). However, one could speculate that 
IFN-based immunotherapy might benefit patients at high risk of relapse due to 
massive lymph node involvement. 
The renal tumour cell vaccine trial investigated the effect of this therapy on 
the risk of progression in 558 patients with stage pT2-3b, pN0-3 M0 RCC who were 
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scheduled to undergo radical nephrectomy at 55 institutions in Germany28. The 
patients were randomly assigned to receive either six intradermal applications of the 
vaccine at 4-week intervals after surgery or no adjuvant treatment. All patients were 
assessed using standardized diagnostic investigations at 6-month intervals for a 
minimum of 4.5 years28. At 5-year and 70-month follow-up, the HRs for tumour 
progression were 1.58 (95% CI 1.05-2.37) and 1.59 (95% CI 1.07-2.36), respectively, in 
favour of the vaccine group (p=0.0204). Progression-free survival in the vaccine group 
was 77.4% at 5-years and 72% at 70-months. In the control group progression-free 
survival at these time points was 67.8% and 59.3%, respectively28. 
Although the results were positive, this study was criticized for huge 
methodological biases, including unblinded treatment assignment, a substantial 
imbalance in patient characteristics (76% of those in the vaccine group had clear cell 
histology versus only 68% in the control group) and a high number of protocol 
violations (87 of 276 patients allocated to vaccine and 55 of 277 patients allocated to 
observation did not receive the allocated treatment). The high number of patients 
who withdrew consent and the lack of an in extenso publication reporting on overall 
survival results also affected the overall quality of the study. Moreover, manufacture 
of the vaccine was complex and expensive. 
In 2008, the efficacy of an autologous, tumour-derived, heat-shock protein-
peptide complex (HSPPC-96) as an adjuvant treatment was studied in 819 patients at 
high risk of recurrence after resection of locally advanced RCC29. No difference was 
found in relapse-free survival between patients who received HSPPC-96 and those 
who did not receive treatment after nephrectomy. However, a subgroup analysis of 
the study reported a trend towards an improvement in RFS in patients with early stage 
disease who received HSPPC-96 (HR 0.576, 95% CI 0.324-1.023; P=0.056)29. 
Finally, the results of the first adjuvant trial using a targeted agent were 
published in 201733. This study compared girentuximab, an anti-anhydrase carbonic IX 
(CAIX) monoclonal antibody, to observation in 864 patients with radically resected 
kidney cancer. CAIX is a tumor-associated transmembrane protein that is 
overexpressed in VHL-mutated clear cell kidney cancers and other hypoxic solid 
tumors but is expressed at low levels in most normal tissues including normal kidney34. 
Despite the strong rationale for use of this agent in kidney cancer, girentuximab 
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therapy yielded no statistically significant improvement in DFS (HR 0.97, 95% CI 0.79-
1.18) or overall survival (HR 0.99, 95% CI 0.74-1.32) compared with placebo33. A 
subgroup analysis showed a nonsignificant trend towards benefit of girentuximab 
therapy with increasing CAIX score33. These inconclusive findings highlight the 
potential risk of trial failure as a result of testing novel targeted agents without 
selecting or enriching the study population for the relevant target, a mistake that has 
hampered the development of several anticancer agents.  
As all the published trials have yielded negative or at best highly biased and 
inconclusive results, no adjuvant therapy has emerged as a standard treatment for 
patients with kidney cancer. Credible reasons for these dismaying results include the 
use of extremely low active (at least in kidney cancer) treatment strategies (e.g. 
chemotherapy, hormonal agents or ‘old-fashioned’ radiotherapy), limited patient 
numbers in many studies, the enrollment of patients with very different prognoses 
(sometimes including those with metastatic disease) in the same trials, the use of 
different disease classifications and staging systems in different studies, a lack of 
understanding of the mechanisms of action of immunotherapeutics (cytokines and 
vaccines) and the use of end points other than DFS and OS, which are the only 
recommended end points for this setting35. 
We performed a meta-analysis of aggregated data from phase III RCTs and 
found no clinical benefit of any type of adjuvant therapy for kidney cancer in relation 
to the primary end point of 5-year RFS or the secondary end points of 2-year RFS and 
2 year and 5-year OS36. Our additional subgroup analysis showed no significant 
qualitative or quantitative interaction between different adjuvant strategies. 
However, we did observe nonsignificant positive effects in terms of 5-year RFS in the 
qualitative interaction between different adjuvant treatment strategies, particularly 
between vaccines, cytokines and other types of treatment. These findings suggest that 
the lack of equivalence between different treatments in terms of efficacy could be 
related to the nature of the therapeutic intervention itself36. These observations 
suggest that novel adjuvant immunotherapeutic strategies with specific mechanisms 
of action (for example, immune checkpoint inhibitors) might have a role in the future 
treatment of patients with kidney cancer, and hopefully yield a positive outcome.  
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TYROSINE KINASE INHIBITORS 
A number of different genetic alterations with pathogenic consequences have been 
identified in RCC and particularly in ccRCC, which is by far the most common histotype. 
These alterations include allele deletion in the Von Hippel Lindau tumor suppressor 
gene (VHL), mutations in the remaining VHL allele and VHL gene inactivation through 
gene silencing by methylation37-39. Biallelic VHL gene inactivation is observed in the 
vast majority of ccRCCs37-39. The product of the VHL gene, pVHL, is a 213 amino acid 
protein component of an ubiquitin ligase complex that mediates the physiologic 
cellular response to hypoxia. In conditions of normoxia, pVHL binds the hypoxia-
inducible factors (HIF)-1a and HIF-2a, leading to their ubiquitination and subsequent 
proteasomal degradation. In the setting of hypoxia or in the presence of a defective 
VHL gene, HIFs are not degraded and their accumulation leads to the transcription of 
hypoxia-inducible genes, which ultimately results in the hyperproduction of a number 
of pro-angiogenic cytokines, including the vascular endothelial growth factor 
(VEGF)40,41. For this reason, agents that target VEGF and VEGF receptor (VEGFR) 
pathways have been developed as agents for the treatment of metastatic RCC (Figure 
1).  
To date, 5 phase III RCTs have been designed to evaluate the efficacy of VEGFR-
targeted therapies versus placebo in patients with early (that is, non-metastatic) RCCs 
at high-risk of relapse following nephrectomy42-46. The results of four of these trials, 
which investigated the effects of 1 year of treatment with sunitinib, sorafenib, 
pazopanib and axitinib on disease-free survival after nephrectomy in patients with 
predominantly ccRCC have now been published (Table 3).42-44  
The multi-center, international double-blind placebo-controlled S-TRAC trial 
investigated the efficacy of sunitinib in 615 patients at high-risk of recurrence of RCC 
(according to the UISS model) following surgical removal of the primary tumour43. 
Patients were randomly assigned 1:1 to receive either 50 mg sunitinib once daily on a 
four weeks on and 2 weeks off treatment schedule or placebo for 1 year. The median 
DFS was significantly higher in the sunitinib group (6.8 years) than in the placebo group 
(5.6 years; HR 0.76, 95% CI 0.59–0.98, P=0.03). Based on these data, the US FDA 
approved sunitinib for the adjuvant treatment of adult patients at high-risk of 
recurrent RCC following nephrectomy in November 201747.  
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The Adjuvant Sorafenib or Sunitinib for Unfavorable Renal Carcinoma 
(ASSURE) study, which included 1,943 patients with RCC at intermediate or high-risk 
of relapse (according to the UISS model), did not find an improvement in DFS or overall 
survival with 1 year of adjuvant sunitinib or sorafenib therapy compared with 
placebo42. During this study, the starting doses were reduced due to toxicity issues 
from 50 mg to 37.5 mg daily for sunitinib and from 800 mg to 400 mg for the first one 
or two cycles of sorafenib. The primary analysis reported a median DFS of 5.8 years 
(Interquartile range [IQR] 1.6-8.2) in the sunitinib group (HR 1.02, 97.5% CI 0.85-1.23, 
p=0.8038), 6.1 years (IQR 1.7-not estimable [NE]) in the sorafenib group (HR 0.97, 
97.5% CI 0.80-1.17, p=0.7184) and 6.6 years (IQR 1.5-NE) in the placebo group42. 
Furthermore, a secondary analysis of the trial results found that neither the prognostic 
category of the tumor nor the dose intensity of therapy altered the lack of difference 
in DFS or overall survival with the adjuvant therapies versus placebo48. 
Similarly, the Pazopanib As Adjuvant Therapy in Localized/Locally Advanced 
RCC After Nephrectomy (PROTECT) study, which evaluated the efficacy of 1 year of 
pazopanib as an adjuvant therapy for patients with locally advanced RCC at high-risk 
of relapse after surgery based on TNM risk stratification, failed to report a DFS or 
overall survival benefit44. PROTECT was originally designed with pazopanib 800 mg 
once daily as the starting dose. However, similar to the ASSURE trial, the primary 
objective of PROTECT had to be amended to study DFS in a cohort that received a 
reduced starting dose of pazopanib (600 mg) owing to a high rate of adverse events. 
Unfortunately, no DFS benefit was observed for pazopanib 600 mg once daily 
compared to placebo. The DFS results of the primary analysis of the intention-to-treat 
(ITT) cohort favoured pazopanib 600mg but did not show a significant improvement 
over placebo (HR 0.86; 95% CI 0.70–1.06; P = 0.165)44. By contrast, the secondary 
analysis of DFS in the 800mg pazopanib subgroup of the ITT cohort (n = 403) yielded 
an HR of 0.69 (95% CI 0.51–0.94)44, suggesting superiority compared with placebo. 
However, a higher rate of treatment discontinuations owing to adverse events 
(particularly hypertension, fatigue and hand-foot syndrome) were observed in this 
group of patients. Interestingly, a post hoc analysis of the PROTECT trial data 
concluded that higher pazopanib exposure was associated with improved DFS and did 
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not increase the rate of treatment discontinuations or grade 3 (severe) and 4 (life-
threatening) adverse events, with the exception of hypertension49. 
The European Association of Urology (EAU) Renal Cell Carcinoma Guideline 
Panel performed a pooled analysis of the ASSURE and S-TRAC data to assess the 
potential impact of 1 year of adjuvant sunitinib therapy on DFS and adverse events50. 
This analysis failed to detect a statistically significant improvement in DFS or overall 
survival with adjuvant VEGFR-targeted therapies. As expected, high-grade adverse 
events (e.g hypertension, fatigue and hand-foot syndrome) were more frequent in 
patients treated with adjuvant sunitinib than in those who received placebo. The EAU 
panel, which included representatives from a patient advocate group (The 
International Kidney Cancer Coalition), also rated the quality of the evidence, the 
harm-to-benefit ratio, patient preferences and costs. Following a vote, they reached 
a consensus not to recommend adjuvant therapy with sunitinib for patients with high-
risk RCC after nephrectomy50. Interestingly, the European Medical Agency (EMA) 
reached the same conclusion and in contrast to the US FDA, decided in 2018 not to 
consider adjuvant sunitinib for approval based on the S-TRAC data51. 
The S-TRAC results and the pazopanib exposure data from PROTECT suggest a 
possible association between drug exposure and improved DFS43,49. Trial investigators 
have suggested that patients who are able to tolerate a full-dose regimen may 
experience prolonged DFS49. However, given the high rate of toxicity attrition in these 
trials, it is unlikely that full doses of adjuvant VEGFR-targeted therapy would be 
tolerable for the majority of patients in the real world setting. As mentioned above, 
reductions of the initially planned starting doses were required to reduce the rate of 
adverse events in the ASSURE and PROTECT studies42,44 and all three studies were 
burdened by drug discontinuations related to VEGFR-TKI toxicity42-44. Although the 
reduction in starting dose ameliorated the toxicities observed in the ASSURE trial, it is 
remarkable that 55% of patients who received reduced dosages of sunitinib or 
sorafenib still experienced high-grade adverse effects42. Moreover, the post-hoc 
subset analyses that evaluated dose intensity in the ASSURE trial found no relationship 
with outcome48. 
In 2018, another adjuvant trial, the axitinib versus placebo in patients at high 
risk of recurrent renal cell carcinoma (ATLAS) study, was stopped owing to futility at a 
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pre-planned interim analysis at 203 DFS events45. The available data show no 
significant difference in DFS according to the independent review committee (IRC) 
assessment (HR  0.870, 95% CI 0.660-1.147, p=0.3211). In the highest-risk 
subpopulation, a 36% and 27% reduction in risk of a DFS event with axitinib was 
observed in the investigator assessment (HR 0.641, 95% CI 0.468-0.879, p=0.0051) and 
IRC assessment (HR 0.735, 95% CI 0.525-1.028, p=0.0704), respectively. The overall 
survival data were not mature. 
Two ongoing post-nephrectomy RCTs are evaluating the efficacy of adjuvant 
sorafenib therapy for 1 year or 3 years (SORCE study)46, and everolimus for 54 weeks 
(EVEREST study)52 (Supplementary table 2). The SORCE results are expected in the first 
few months of 2019, whereas the estimated study completion date for EVEREST is 
October 202152. However, given the disappointing findings discussed above, positive 
results seem unlikely. 
As the mechanism of action of VEGF-TKIs is inhibition of angiogenesis, one 
might speculate that use of these drugs as adjuvant therapy would not eradicate 
occult disease (Box 2). Indeed, these agents failed to eradicate occult disease in other 
types of cancer53, including colorectal cancer54. Neoangiogenesis may not be present 
in very early subclinical metastases, therefore, these lesions may not be susceptible 
to inhibition of neovascularization. In the adjuvant setting, inhibition of 
neoangiogenesis using VEGFR-TKIs in patients with subclinical metastases might only 
delay, rather than prevent, the radiographic progression of their mostly asymptomatic 
lesions. Although such a delay might result in prolonged DFS, it is questionable if this 
prolongation would translate into a clinically meaningful benefit in the absence of 
proven overall survival benefits. In view of this uncertainty, patients face the dilemma 
of whether to accept the toxicity of full-dose treatment in order to take advantage of 
the potential full-dose effect or to continue treatment at a lower dose that is more 
tolerable but has not been shown to be improve DFS. Importantly, it is clinically 
evident that patients who are potentially cured of cancer are willing to accept a 
completely different trade-off between efficacy (i.e. reduction in the risk of relapse) 
and toxicity (that is, they are less likely to accept a low efficacy, highly toxic therapy), 
compared to those with metastatic disease.  
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IMMUNE CHECKPOINT INHIBITORS 
The immune checkpoint inhibitors anti-PD-1, anti-PD-L1 and anti-CTLA4 have been 
reported to show efficacy in metastatic RCC either as monotherapies or in 
combination with other agents including VEGF-targeted therapies55-58. This success 
has generated enthusiasm to test these therapies in the adjuvant setting. Five phase 
III RCTs are currently exploring the effect of immune checkpoint inhibitor therapy in 
the adjuvant setting for loco-regional high-risk RCC59-63 (Supplementary table 3). The 
rationale for use of these therapies is that immune checkpoint inhibition might be 
more effective than VEGFR-targeted therapy in eliminating circulating tumour cells 
and micrometastases (Figure 2).  
Preclinical and early clinical studies suggest that neoadjuvant immunotherapy 
(that is treatment before nephrectomy) might have increased efficacy compared with 
adjuvant immunotherapy (following primary tumour resection) for eradicating 
metastatic disease64. The rationale for a neoadjuvant strategy is that it enables the 
primary tumour antigens to prime the immune response against early occult disease. 
The ongoing PROSPER phase III trial of nivolumab in patients with ≥T2 or T any N+ RCC 
includes a short neoadjuvant period as well as adjuvant therapy59. The investigators 
plan to enroll 766 patients. As nephrectomy will potentially be deferred in the control 
group for 4 weeks, the study is designed as an unblinded trial with observation rather 
than placebo in the control group. 
Currently, no combinations of immune checkpoint inhibitors and VEGF-
targeted therapies are being tested in the adjuvant setting. Given the problems of 
tolerability, it seems unlikely that multi-modal treatments using these agents would 
be a rational strategy for adjuvant therapy. 
 
PRESERVATION OF KIDNEY FUNCTION 
In patients who undergo radical resection for localized RCC, morbidity related to 
chronic kidney disease (CKD) as a result of loss of nephron mass and/or complications 
related to comorbid disease is an important issue. The prevalence of CKD in patients 
with RCC is twice that of the general population, varying from 10% among those 
presenting with a small renal mass to 26% among those with a tumour, irrespective of 
size and even prior to surgical resection65. Moreover, retrospective studies in patients 
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with kidney cancer have reported that the prevalence of CKD increased from 10-26% 
before tumour resection to 16%–52% after surgery66-67. Partial nephrectomy results 
in a mean decrease in glomerular filtration rate (GFR) of 13 ml/min per 1.73 m2 (30%) 
and reduction in renal volume seems to be a prognostic factor for GFR decline68. 
Nephrectomy is also associated with a 33.7% risk of acute kidney injury (AKI)61 and 
postoperative AKI69-71 is a key determinant of GFR decline. Importantly, patients with 
CKD undergoing nephrectomy, even those with T1 tumours, are more likely to die as 
a result of CKD-related complications than as a result of their kidney malignancy65,66. 
Thus, the nephrological management of patients with resected localized RCC should 
focus on preserving kidney function, reducing cardiovascular risk and preventing 
complications (Figure 3). 
In most patients, particularly those with comorbidities including hypertension 
or diabetes65, nephrologists should carefully evaluate kidney function before 
nephrectomy, taking into account the type of planned surgery (either radical or 
nephron-sparing), to evaluate the risk of de novo kidney injury or worsening of pre-
existing CKD. Ideally, such pre-operatory evaluation should performed for all patients, 
but if this is not practical it can be avoided in those who have normal renal function 
and no relevant comorbidities72. Renal nuclear scintigraphy can be used to determine 
the proportional GFR of each kidney in order to better assess the potential impact of 
renal resection (either partial or radical nephrectomy)73. Optimization of glycaemic 
and blood pressure control and prevention of AKI through avoidance of nephrotoxins 
and renal hypoperfusion also reduces the risk of postoperative deterioration of GFR65.  
The evaluation of tumour nephrectomy specimens has always centred around 
the neoplastic renal mass, but careful assessment of the non-neoplastic kidney 
parenchyma may reveal the presence of undiagnosed common non-neoplastic renal 
diseases such as nephro-angiosclerosis or glomerulonephritis, and provide a wealth of 
information regarding future risk of CKD and its progression. Since 2010 the College 
of American Pathologists has required that the non-neoplastic parenchyma is 
evaluated and reported for every renal malignancy74. However, a 2012 survey of 
European genitourinary pathologists found that >25% do not examine the non-
neoplastic part of the kidney in nephrectomy specimens75. 
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After major kidney surgery, patients should undergo nephrology evaluation in 
order to minimize future deterioration in kidney function65,72. In these patients, the 
timing of follow-up is dictated by the residual renal function post-nephrectomy. In the 
US, some patients who undergo radical resection of kidney tumours will receive 
adjuvant sunitinib therapy. Around 30% of these patients will ultimately relapse so 
will require active oncological treatment with either VEGFR-TKI or immune checkpoint 
inhibitors. As concomitant CKD increases the risk of use of suboptimal dose-intensities 
and treatment-related toxicities, especially when VEGFR-TKI are used76,77, this issue 
highlights the key importance of preventing deterioration in kidney function in 
patients with kidney cancer68,69,78,79. 
 
CONCLUSIONS 
Over the past two decades, the survival of patients with metastatic RCC has improved 
substantially80. Among patients with radically resected tumours, however, the lack of 
active adjuvant treatments means that the risk of dying because of metastatic relapse 
has not decreased. The main reasons for this failure are difficulties in clearly 
identifying patients who are at high risk of relapse, historic use of poorly active 
treatments, tolerability issues with novel targeted agents leading to the use of 
suboptimal doses and limited knowledge of the genetic and molecular mechanisms 
that lead to the occurrence of metachronous metastases. Furthermore, the results of 
the only two positive adjuvant trials reported to date are inconclusive and thus 
surrounded by a huge amount of uncertainty. 
Novel immune checkpoint inhibitors hold promise for the adjuvant therapy of 
RCC. However, improved patient selection and stratification (on the basis of risk of 
relapse), smarter clinical trial design, the use of active, biology driven treatments and 
improved management of therapy (to maintain ideal dose intensities) is required to 
prevent the future failure of these and other novel agents. Finally, multidisciplinary 
management of all patients with RCC, including those potentially cured by surgery, is 
mandatory. In particular, input from nephrologists is important to minimize loss of 
renal function following nephrectomy, reduce associated morbidity and mortality and 
manage renal toxicities from oncological treatments. 
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KEY POINTS 
 Effective adjuvant treatments for kidney cancer are needed to reduce the risk 
of recurrence and of dying of metastatic disease. 
 To date, almost all of the tested adjuvant agents have failed to demonstrate 
any benefit in clinical trials; the two positive trials were criticized for 
methodological reasons and conflicting results. 
 Only one drug — sunitinib — has been approved for the adjuvant treatment 
of kidney cancer in the US; however this drug has not been approved as an 
adjuvant therapy in Europe. 
 Positive results with immune checkpoint inhibitors in metastatic renal cell 
carcinoma suggest that these agents might also be effective adjuvant 
therapies; trials of these agents are underway. 
 Preservation of kidney function in patients with renal cell carcinoma is 
important to reduce morbidity; therefore multidisciplinary management 
should be mandatory for almost all patients with radically resected kidney 
cancer. 
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Box 1 | TNM staging of kidney tumours 
Tumour (T) 
Tx: The primary tumor cannot be assessed 
T0: No evidence of a primary tumor 
T1: Kidney-confined tumor <7 cm in diameter 
 1a: <4 cm 
 1b: >4 cm and <7 cm 
T2: Kidney-confined tumor >7 cm in diameter 
 2a: >7 cm and <10 cm 
 2b: >10 cm 
T3: The tumor is growing into a major vein or into tissue around the kidney, but it is 
not growing into the adrenal or beyond Gerota’s fascia 
 3a: the tumor is growing into the renal vein or into fatty tissue around the 
kidney 
 3b: the tumor is growing into intra-abdominal vena cava  
 3c: the tumor is growing into the vena cava above the diaphragm 
T4: The tumor has spread beyond Gerota’s fascia or into the adrenal gland 
 
Nodes (N) 
Nx: Regional lymph nodes cannot be assessed 
N0: No spread to nearby lymph nodes 
N1: Tumor has spread to nearby lymph nodes 
 
Metastases (M) 
M0: No distant metastases 
M1: Distant metastases 
 
TNM stage 
Stage I 
 T1, N0, M0 
Stage II 
 T2, N0, M0 
Stage III 
 T1 or T2, N0, M0 
 T3, N0 or N1, M0 
Stage IV 
 T4, any N, M0 
 Any T, any N, M1 
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Box 2 | Possible reasons for failure of VEGFR-TKIs in the adjuvant setting 
 
Biolological 
 Inability to eradicate occult disease as antiangiogenic agents act on tumor 
blood vessels rather than tumour cells 
 Inadequacy of 1-2 years of antiangiogenic treatment for a malignancy that is 
often characterized by late relapses even decades after resection of the 
primary tumour; in preclinical models, tumor angiogenesis starts regrowing 
within a few days of withdrawal of the antiangiogenic agent 
Pharmacological 
 Poor tolerability – a major issue in potentially cured patients – could result in 
an excess of dose reductions and treatment pauses and ultimately lead to a 
suboptimal dose intensity of the adjuvant treatment; a direct relationship 
exists between the AUC of VEGFR-TKIs and their activity 
Patient related 
 Risk of non-adherence to treatment or treatment withdrawal in patients who 
often consider themselves to be cured by surgery so are not willing to accept 
treatment-related adverse events 
VEGFR-TKI, Vascular Endothelial Growth Factor Receptors Tyrosine Kinase Inhibitors; AUC, area under 
the plasma drug concentration-time curve. 
 
 
Figure 1 | Mechanisms of action of VEGFR-TKI in RCC. In normoxic conditions, VHL 
binds hypoxia-inducible factor 1α (HIF1α) and HIF1β and targets them for proteasomal 
degradation. Genetic loss or inactivation of the VHL gene owing to mutation, deletion 
or hypermethylation leads to the accumulation of HIF1α and HIF1β, which dimerize 
and translocate to the nucleus. The HIF complex induces the transcription of hypoxia-
inducible genes and the overproduction of proangiogenic factors including vascular 
endothelial growth factor (VEGF) and platelet-derived growth factor (PDGF). Binding 
of these proangiogenic factors to their receptors on endothelial cells leads to the 
stimulation of angiogenesis, which enables the tumor to grow beyond 2-3 mm and to 
access the general circulation — the first step in the process of metastasis. 
Angiogenesis can be inhibited by blocking circulating VEGF using monoclonal 
antibodies such as bevacizumab or by inhibiting the tyrosine kinase activity of the 
VEGFR using tyrosine kinase inhibitors such as pazopanib, sunitinib, sorafenib or 
axitinib.  
 
Figure 2 | Mechanisms of action of immune checkpoint inhibitors in RCC. Immune 
checkpoint blockade using anti-CTLA4, anti-PD-1 and/or anti-PD-L1 monoclonal 
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antibodies removes inhibitory signals that limit T cell responses. CTLA4 inhibitors 
usually act within lymph nodes (i.e. in the periphery) where they block the interaction 
between CTLA4 expressed on naive T cells and B7 expressed on dendritic cells so 
enable the activation and proliferation of tumour antigen-specific T cells. Anti-PD1 and 
anti-PD-L1 usually act within the tumour microenvironment (i.e. centrally) where they 
block interactions between PD-1 expressed on tumour-reactive T cells and PD-L1 
and/or PD-L2 on tumour cells so enhance anti-tumour immune responses.  
 
Figure 3 | The role of nephrologists in the management of resected RCC. The optimal 
management of patients with resected localized RCC should involve a multidisciplinary 
approach with input from oncologists, pathologists and nephrologists. We propose 
that involvement of a nephrologist should be mandatory for all patients with chronic 
kidney disease (CKD), including those receiving adjuvant therapies, with a focus on 
preserving kidney function, reducing cardiovascular risk and preventing 
complications. Nephrology involvement is also required for patients without CKD 
receiving adjuvant therapy if renal toxicity occurs.  
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Table 1 | Commonly used clinico-pathologic predictive models for risk of relapse of 
RCC following surgical resection 
 
Model Predictor variables Histology Outcome predicted Positive predictive value Refs 
UISS  Pathologic stage 
 Nuclear grading 
 ECOG performance status 
Histoype 
independant 
Overall survival in patients 
with non-metastatic and 
metastatic RCC 
 Non-metastatic RCC: 
76.5-86.3% 
 Metastatic RCC: 64-77% 
8 
SSIGN  Pathologic stage (including 
metastasis stage) 
 Nuclear grading 
 Major dimension of the tumour 
 Presence of coagulative necrosis 
Valid only for 
clear cell RCC 
Cause-specific survival 82-88% 11 
Leibovich  Pathologic stage (excluding 
metastasis stage) 
 Nuclear grading 
 Major dimension of the tumour 
 Presence of coagulative necrosis 
Valid only for 
clear cell RCC 
Metastases-free survival >80% 9 
Karakiewicz  Pathologic stage (excluding 
metastasis stage) 
 Nuclear grading 
 Major dimension of the tumour 
 Mode of presentation 
Histoype 
independant 
Cause-specific survival 86-88% 12 
Kattan  Patient’s symptoms (incidental, 
local or systemic) 
 Histology (clear cell, papillary or 
chromophobe) 
 Tumour size 
 Pathological stage 
Valid for clear 
cell, papillary or 
chromophobe 
RCC 
RCC recurrence-free 
survival  
74% 13 
UISS, University of California at Los Angeles (UCLA) Integrated Staging System; ECOG, Eastern 
Cooperative Oncology Group; RCC, renal cell carcinoma; SSIGN, Stage, Size, Grade and Necrosis 
staging system.  
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Table 2 | Selected early randomized trials of adjuvant therapy for radically resected 
kidney cancer* 
 
Study Intervention Patients Results Observations and/or limitations Ref
s N Criteria 
Cytokine-based immunotherapy 
Pizzocaro 
(2001) 
IFN-α2b (6 MU 
i.m. 3 times a 
week for 6 
months starting 
within 1 month 
after surgery) 
versus 
observation 
247 TNM stage II or III: 
 pT3a, N0, M0 
 pT3b, N0, M0 
 pT2/3, N1-3, M0 
No significant difference in 5-year OS 
and event-free survival (control group 
0.665 and 0.671, respectively, 
intervention group 0.660 and 0.567, 
respectively; P = ns for both) 
 IFN-α2b had a statistically 
significant harmful effect in 
patients with pN0 RCC (n = 
97; HR 2.228) 
 IFN-α2b had a protective 
effect in patients with pN2/3 
RCC (n = 13; HR 0.191)  
20 
Vaccines 
Jocham 
(2004) 
Autologous renal 
tumour cell 
vaccine (6 
intradermal ap-
plications at 4-
week intervals 
postoperatively) 
versus 
observation 
558  Stage pT2/3b pN0-3 
M0 
 Patients with pT1 or 
pT4 RCC were 
excluded 
 Patients who had 
undergone surgery 
other than radical 
nephrectomy were 
excluded 
 HR for tumour progression were 
1.58 (95% CI = 1.05-2.37) and 
1.59 (95% CI = 1.07-2.36), 
respectively, in favour of the 
vaccine group (p=0·0204 
 At 5-year and 70-month follow-
up, HRs for tumour progression 
were 1.58 (95% CI = 1.05-2.37) 
and 1.59 (1.07-2.36), 
respectively, in favour of the 
vaccine group (p=0.0204) 
 Vaccination was extremely 
well tolerated 
 Similar quality of life in the 
two groups 
 Study had important 
methodological flaws 
including imbalance in patient 
characteristics and protocol 
violations 
28 
Wood 
(2008) 
HSPPC-96 (25 μg 
intradermally 
once a week for 4 
weeks then every 
2 weeks until 
vaccine supply 
depletion or 
disease 
progression) 
versus 
observation 
818  cT1b/T4, N0, M0 
 cT any, N1-2, M0 
No significant difference in disease 
recurrence, which occurred in 136 
(37.7%) patients in the vaccine group 
and 146 (39.8%) patients in the 
observation group (HR = 0.923, 95% 
CI 0.729-1.169, p=0.506) 
Possible improvement in RFS in 
patients with stage I or II disease 
but the observed difference was 
not statistically significant (HR 
0.576, 95% CI 0.324-1.023, 
P=0.056) 
29 
Monoclonal antibody  
Chamie 
(2017) 
Girentuximab 
(single IV dose of 
50 mg in week 1 
followed by 20 
mg per week from 
weeks 2-24) 
versus placebo 
864 High risk patients defined 
as: 
 pT3/pT4, Nx/N0, M0  
 pTany, N+, M0 
 pT1b/pT2, Nx/N0, M0 
with nuclear grade 3 
or greater 
 No significant difference in DFS 
(HR 0.97, 95% CI 0.79-1.18) or OS 
(HR 0.99, 95% CI 0.74-1.32) 
 Median DFS was 71.4 months in 
the Girentuximab group and not 
reached in the placebo group 
 Median OS was not reached in 
either group 
No difference in safety between 
treatment and placebo groups 
33 
*Adjuvant trials that are extensively discussed within the text of this Review are summerized in this 
table. For a full list of early adjuvant trials see Supplementary table 1. i.m. , intramuscular; MU, mega 
units; TNM, Tumor, Nodes, Metastasis staging system; RFS, relapse-free (or recurrence-free) survival; 
IV, intravenous; HR, hazard ratio; CI, confidence interval; OS, overall survival; IFN, interferon. 
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Table 3 | Phase III trials of VEGFR-TKIs as adjuvant therapies for radically resected 
RCC 
 
Trial Inclusion criteria Treatment (dose*) Patients 
(drug/pla
cebo) 
Disease-free 
survival 
Treatment adherence Refs 
ASSURE 
(NCT0032
6898) 
 pT1b high-grade, 
N0, M0 or N+, M0 
 Clear cell or non-
clear cell RCC 
 ECOG PS 0–1 
 Normal liver and 
haematological 
function 
 Creatinine 
clearance 
>30ml/min/1.73 m2 
Sunitinib (50 mg per 
day for the first 28 
days of each 6-week 
cycle)  
647/647 HR 1.02 (97.5% 
CI 0.85-1.23), P 
= 0.8038 
 42% of patients received the intended dose at 
cycle 3 
 Among patients starting sunitinib at full or 
reduced dose, the rates of treatment 
discontinuation were 44% and 34%, respectively 
42 
Sorafenib (400 mg 
twice per day)  
649/647 HR 0.97 (97.5% 
CI 0.80-1.17), P 
= 0.7184 
 31% of patients received the intended dose at 
cycle 3 
 Among patients starting sorafenib at full or 
reduced dose, the rates of treatment 
discontinuation were 45% and 30%, respectively 
42 
S-TRAC 
(NCT0037
5674) 
 Stage III–IV, M0 
(UISS modified 
criteria) 
 Clear cell RCC 
 ECOG PS 0–2 
Sunitinib (50 mg per 
day on a 4-weeks on, 
2 weeks-off schedule 
for 1 year)  
309/306 HR 0.761 (95% 
CI 0.594-0.975), 
P = 0.030 
 Dose reductions or interruptions because of 
adverse events in 34.3% and 46.4% of patients, 
respectively 
 Treatment discontinuations owing to adverse 
events in 86 patients (28.1%) 
43 
PROTECT 
(NCT0123
5962) 
 pT2 high-grade, 
pT3–4, N0, M0 or 
N+, M0 
 Clear cell RCC 
 KPS≥80% 
Pazopanib (600 mg 
per day with optional 
dose escalation to 
800 mg per day after 
8-12 weeks; 
treatment for 1 year) 
571/564 HR 0.862 (95% 
CI 0.699-1.063), 
P = 0.1649 
 Fewer than 50% of patients completed 
treatment  
 Dose reductions in 51% and 60% of patients in 
the 600 mg and 800 mg groups, respectively 
 Treatment discontinuation due to adverse 
events in 35% and 39% of patients in the 600 mg 
and 800 mg groups, respectively 
44 
ATLAS 
(NCT0159
9754) 
 ≥pT2 and/or N+ 
 Any Fuhrman 
grade 
 ECOG PS 0/1 
 Clear cell RCC 
Axitinib (5 mg twice 
per day for ≤3 years 
with a 1-year 
minimum) 
363/361 HR 0.870; (95% 
CI 0.660-1.147), 
P = 0.3211 
 The percentage of patients with adverse events 
leading to dose reductions (56% versus 8%), 
dose interruptions (51% versus 22%) and 
permanent discontinuations (23% versus 11%) 
was greater in the axitinib group than the 
placebl group 
45 
ECOG PS, Eastern Cooperative Oncology Group Performance Status; HR, Hazard Ratio; CI, confidence 
interval; KPS, Karnofsky performance status; UISS, UCLA Integrated Staging System; AEs, adverse 
events. *In ASSURE, high rates of toxicity-related discontinuation occurred after 1,323 patients had 
enrolled. Therefore, the starting dose for each drug was reduced than individually titrated up to the 
original full doses. The starting doses were amended to 37.5 mg for sunitinib or 400 mg for sorafenib 
for the first 1–2 cycles of therapy. In PROTECT, the trial was originally designed with pazopanib 800 mg 
once daily as starting dose. An amendment to the protocol was introduced to reduce the starting dose 
to 600 mg once daily due to a higher than expected treatment discontinuation; 198 patients received 
a starting dose of 800 mg of whom 53% experienced adverse events and had their dosage reduced and 
51% discontinued treatment. Following protocol amendment 568 patients were recruited; these 
patients served as the group for primary analysis. 
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Supplementary table 1 | Early randomized trials of adjuvant therapy for radically 
resected kidney cancer 
 
Miscellaneous  
Author, year No. Interventions Stage/risk class 
of treated 
patients 
Main results Observations/criticisms Refs* 
Kjaer M, et al., 
1987 
72 Arm A – 
Radiotherapy (50 
Gy in 20 fractions 
of 2.5 Gy each, 
four fractions per 
week) to the 
kidney bed, ipsi- 
and contralateral 
lymph nodes 
Arm B – 
observation 
 33 and 32 pts, 
out of the 65 
analyzed 
were in stage 
II and III, 
according to 
the Holland 
classification, 
respectively 
 No differences in 
RFS 
 Pts with stage II 
tumours survived 
significantly better 
than those with 
stage III tumours 
(p<0.05), but no 
significant 
differences in 
survival has been 
demonstrated 
between pts 
randomized to 
postoperative 
radiotherapy or 
observation 
 7 pts were excluded from 
analysis due to major 
protocol violations;  
 44% of treated pts had 
significant complications 
from stomach, duodenum 
or liver; in 19% of them, 
postirradiatory 
complications lead (or 
contributed) to death 
19 
Pizzocaro G, et 
al., 
1987 
136 Arm A – 
Medroxyprogeste
-rone acetate 500 
mg per os, 3 
t.i.w., for 1 year 
Arm B – 
observation 
 M0 pts  No differences in 
RFS (32.7% vs 
33.9%) of relapsing 
pts in the 
treatment and 
control arm, 
respectively 
 56.9% of pts experienced 
treatment-related 
complications 
30 
Naito S, et al., 
1997 
71 Arm A – UFT 
(Tegafur and 
Uracil in a 1:4 
molar concen-
tration) 300 to 
600 mg (as 
Tegafur) o.d., for 
2 years 
Arm B – 
observation 
 Stage I or II 
according to 
Robson (54 
out of 71 
were pT2)  
 No differences in 5-
year non 
recurrence rates 
(80.5% for UFT-
treated pts vs 
77.1), as well as 5-
year renal cell 
carcinoma specific 
survival (90.6% vs 
82.1%) 
 5 pts were not evaluable; 
 2 pts received 
immunotherapy together 
with UFT; 
 2 pts asked to discontinue 
the drug due to adverse 
gastro-intestinal effects; 
 1 patient was lost to the 
follow-up at 8 weeks after 
starting therapy 
31 
Margulis V, et al. 
2009 
46 Arm A – 
Thalidomide 100 
mg o.d. per os, 
for 2 weeks, then 
200 mg o.d. for 2 
weeks, followed 
by the maximum 
dose of 300 mg 
o.d. for a 
maximum of 2 
years, or until 
untolerable 
toxicity 
 T2 (high 
grade, any N), 
T3/T4 (any 
grade, any N), 
or node-
positive (any 
grade, any T) 
tumors 
 any histologic 
subtype 
 Pts on Thalidomide 
had inferior 2- and 
3-year probabilities 
of RFS, compared 
with controls 
(47.8% vs 69.3% 
and 28.7% vs 
69.3%, res-
pectively) 
 2- and 3-year CSS 
was similar for 
both groups 
 Treatment stopped at first 
interim analysis, after a 
median follow up of 43.9 
months (range: 9.7-74.2 
months), given the minimal 
likelihood that adjuvant 
Thalidomide would 
demonstrate the clinically 
significant benefit projected 
32 
 31 
Arm B – 
observation 
Chamie K, et al., 
2017 
864 Arm A – single 
loading i.v. dose 
of Girentuximab, 
50 mg (week 1), 
followed by 
Girentuximab 20 
mg/week (weeks 
2-24) 
Arm B – placebo 
High risk pts 
defined as: 
 pT3/pT4, 
Nx/N0, M0  
 pTany, N+, 
M0 
 pT1b/pT2, 
Nx/N0, M0 
with nuclear 
grade 3 or 
greater 
 No differences in 
DFS (HR = 0.97, 
95% CI = 0.79-1.18) 
or OS (HR = 0.99, 
95% CI = 0.74-1.32) 
 Median DFS was 
71.4 months for 
Girentuximab and 
never reached for 
placebo  
 Median OS was 
never reached 
regardless of 
treatment 
 No differences in safety 
between treatment and 
placebo arm 
33 
Vaccines  
Author, year No. Interventions Stage/risk class 
of treated 
patients 
Main results Observations/criticisms Refs 
Adler A, et al., 
1987 
43 Arm A – immuno-
hormono-therapy 
arm 
(immunotherapy 
consisted of 
autologous irra-
diated tumor 
cells, admixed 
with bacillus 
Calmette-Guérin, 
administered by 
the intra-dermal 
and 
endolymphatic 
route) 
Arm B –
hormonotherapy 
alone (HT) 
 Stage I to IV 
(i.e. included 
also 
metastatic 
pts) 
 Not statistically 
significant trend in 
favor of the 
experimental arm, 
over the control 
one, in terms of 
DFI in stages I-III 
(i.e. localized) 
disease  
 Mixed radically resected, 
with metastatic pts 
 A correlation was 
established between 
induction of cutaneous 
delayed hypersensitivity to 
auto-logous irradiated 
tumor cells and prolonged 
PFI and OS 
26 
Galligioni E, et al. 
1996 
120 Arm A – active 
specific 
immunotherapy 
consisting of 3 
intradermal 
injections of 107 
autologous 
irradiated tumor 
cells mixed with 
107 Bacillus 
Calmette-Guerin 
(in the first 2 
vaccinations) 
Arm B – 
observation 
 Stage I (just 3 
pts) to III, 
according to 
the TNM 
staging 
system 
 At least hylar 
lymphade-
nectomy was 
performed in 
all pts 
 The probability of 
5-year DFS was 
63% for treated 
patients, and 72% 
for controls (p = 
n.s.), respectively 
 The 
corresponding 
probability of 5-
year overall 
survival (OS) was 
69% and 78%, 
respectively (p = 
n.s.) 
 One month after 
completing active specific 
immunotherapy, 38 of 54 
immunized patients showed 
a significant (p < 0.01) DTCH 
response to autologous 
tumor, but not to 
autologous normal renal 
cells 
 No significant differences in 
DFS and OS were observed 
in the treated pts, according 
to the intensity of the DTCH 
response 
27 
Jocham D, et al. 
2004 
379 Arm A – six 
intradermal ap-
plications of an 
 Stage pT2/3b 
pN0-3 M0 
 HR for tumor 
progression were 
1.58 (95% CI = 
 Vaccination was extremely 
well tolerated 
 QoL was similar in the two 
28 
 32 
autologous renal 
tumour cell 
vaccine at 4-week 
intervals 
postoperatively 
Arm B – 
observation 
 pT1 as well as 
pT4 were 
excluded 
 Surgery other 
than radical 
nephrectomy 
was an 
exclusion 
criterion 
1.05-2.37) and 1.59 
(95% CI = 1.07-
2.36), respectively, 
in favour of the 
vaccine group 
(p=0·0204 
 5-year and 70-
month PFS rates 
were 77.4% and 
72%, respectively, 
in the vaccine 
group and 67.8% 
and 59.3%, 
respectively, in the 
control group 
study arms 
 Study had significant 
methodological flaws (see 
text) 
Wood C, et al. 
2018 
818 Arm A – 
Vitespen™ 
vaccine (i.e. an 
heat-shock 
protein 
[glycoprotein 
96]–peptide 
complex derived 
from autologous 
tumors) give 
intradermally at 
the dose of 25 μg 
once a week for 4 
weeks, then every 
2 weeks until 
vaccine supply 
depletion or 
disease 
progression 
Arm B – 
observation 
 cT1b/T4, N0, 
M0 
 cTany, N1-2, 
M0 
 Recurrences were 
reported in 136 
(37.7%) patients in 
the vaccine group 
and 146 (39.8%) in 
the observation 
group (HE = 0.923, 
95% CI = 0.729-
1.169, p=0.506) 
 Possible improvement in 
RFS in pts with early stage 
(stage I or II) disease, 
though the observed 
difference was not 
statistically significant (HR = 
0.576, 95% CI = 0.324-
1.023, p=0.056) 
29 
Cytokine-based immunotherapy  
Author, year  No. Interventions Stage/risk class 
of treated 
patients 
Main results Observations/criticisms Refs 
Pizzocaro G, et al. 
2001 
247 Arm A - IFN-
2b(6 MU i.m. 
tiw for 6 months 
starting within 1 
month from 
surgery) 
Arm B – 
observation 
Stage II or III 
according to the 
1987 TNM 
classification: 
 pT3a, N0, M0 
 pT3b, N0, M0 
 pT2/3, N1-3, 
M0 
 5-year overall and 
event-free survival 
probabilities were 
0.665 and 0.671, 
respectively, for 
controls, and 0.660 
and 0.567, 
respectively, for 
the treated group 
(p = n.s. for both) 
 A statistically significant 
harmful effect of IFN-2b in 
the 97 treated pN0 patients 
(HR = 2.228), and a 
protective effect in the 13 
treated pN2/3 patients 
(0.191) was observed  
20 
Messing E, et al., 
2003 
283 Arm A – Up to 12 
cycles of IFN-NL, 
daily for 5 days a 
week, every 3 
weeks (3 MU/m2, 
day 1, 5 MU/m2, 
 pT3 
 pT4a 
 Any N+ 
(according to the 
1987 TNM 
classification) 
 Median OS: 7.4 
years in the 
observation arm vs 
5.1 years in the 
treatment arm 
(log-rank p = 0.09) 
 A proportional hazards 
model examining the 
effects of treatment arm 
and time to recurrence on 
survival after recurrence 
among pts who recurred 
21 
 33 
day 2, 20 MU/m2, 
days 3, 4 and 5) 
Arm B – 
observation 
 Median RFS: 3.0 
years in the 
observation arm vs 
2.2 years in the 
treatment arm (p = 
0.33) 
found that random 
assignment to IFN-NL (p = 
0.009) and shorter time to 
recurrence (p < 0.0001) 
were independent 
predictors of shorter 
survival 
 Grade 4 AEs occurred in 
11.4% of IFN-NL-treated 
pts 
Clark JI, et al. 
2003 
69 Arm A – IL-2 
600.000 UI/Kg i.v. 
bolus over 15’, 
every 8 hours on 
days 1 to 5, and 
again on days 15 
to 19, for a 
maximum of 28 
doses 
Arm B – 
observation 
 pT3b-c  
 pT4 
 pN1-3 
 completely 
resected M1 
(pT3b and pN1 
patients allowed 
after an amend-
ment done in 
order to increase 
accrual) 
 
 2- and 3-year DFS 
was 48% and 32% 
for IL-2 treated pts, 
and 55% and 45% 
for observed pts, 
respectively 
 2- and 3-year OS 
was 86% and 80% 
for IL-2 treated pts, 
and 86% and 86% 
for observed pts, 
respectively 
 Early study closure occurred 
when an interim analysis 
determined that the 30% 
improvement in 2-year DFS 
could not be achieved 
despite full accrual 
 88% of the 33 pts treated 
with IL-2 experienced at 
least one grade 3 or 4 AE, 
hypotension being the 
commonest 
22 
Passalacqua R, et 
al. 
2007 
310 Arm A – s.c. IL-2 
for 5 days a week 
during a 4-week 
period at the 
dose of 1 MU/m2 
b.i.d. on days 1 
and 2, and o.d. on 
days 3, 4 and 5 + 
IFN- 1.8 MU/m2 
on days 3 and 5 of 
each week; cycles 
as described were 
repeated every 4 
months for the 
first 2 years, and 
then every 6 
months for the 
subsequent 3 
years 
Arm B – 
observation 
 pT2-3b, N0-3, 
M0 
(according to the 
1993 UICC 
classification) 
 RFS at 5 years was 
0.73 in both the 
treatment group, 
as well as in the 
control one HR = 
0.84) 
 5-year OS was 0.80 
and 0.85 in the 
treatment and 
control groups, 
respectively (HR = 
1.07) 
 RFS survival curves were 
superimposible during the 
first 5 years of observation 
and then tended to 
separate (without any 
statistical significance) 
 Unplanned subgroup 
analysis showed a positive 
effect of the treatment for 
pts with age 60 years or 
younger, pN0, tumor grade 
1 or 2, and pT3a stage; 
among pts with at least 2 of 
these factors, 
immunotherapy had a 
positive effect on RFS (HR = 
0.44), as compared with pts 
with less than 2 factors (HR 
= 2.27) 
24 
Chemo-immunotherapy  
Author, year No. Interventions Stage/risk class 
of treated 
patients 
Main results Observations/criticisms Refs 
Atzpodien J, et al., 
2005 
203 Arm A – one 8-
week treatment 
cycle of s.c. IFN-
2a (5 MU/m2, 
day 1, weeks 1 + 
4; days 1, 3, 5, 
weeks 2 + 3; 10 
MU/m2, days 1, 3, 
5, weeks 5–8), s.c. 
High risk patients 
defined as: 
 pT3b/c, pN0; 
 pT4, pN0 
 pN+ 
 M+ (solitary 
lesion), but 
R0 
 2-, 5-, and 8-year 
survival probabi-
lities were 81, 58, 
and 58% on the 
experimental arm, 
and 91, 76, and 
66% on the 
observation arm 
 Included also patients with 
solitary metastased, though 
radically resected 
 18 patients did receive 
previous systemic 
treatments (no further 
explanations) 
 No safety data available 
23 
 34 
IL-2 (10 MUm2, 
b.i.d., days 3–5, 
weeks 1 + 4; 5 
MU/m2, days 1, 3, 
5, weeks 2 + 3) 
and i.v. 5-FU 
(1000 mg/m2, day 
1, weeks 5–8); a 
20% dose 
reduction of s.c. 
IL-2 was given to 
patients ≥ 60 
years of age 
Arm B – 
observation 
 2-, 5-, and 8-year 
RFS probabilities 
were 54, 42, and 
39% on the 
experimental arm, 
with a median RFS 
of 2.75 years 
(range: 0–8.2 
years), and 62, 49, 
and 49% on the 
observation arm, 
with a median RFS 
of 4.25 years 
(range, 0–9.7 
years)  
 OS was 
significantly 
decreased (log 
rank P = 0.0278) 
after treatment 
with 
immunochemother
apy (range: 0.2–8.4 
years), when 
compared with the 
control (range: 
0.3–9.7 years) 
Aitchinson M, et 
al., 
2014 
309 Arm A – IL-2 (20 
MU/m2, s.c., days 
1, 3 and 5, week 
1; 5 MU/m2, days 
1, 3 and 5, weeks 
2-3; 20 MU/m2, 
days 1, 3 and 5, 
week 4), IFN- (6 
MU/m2, s.c., day 
1, week 1; 6 
MU/m2, days 1, 3 
and 5, weeks 2-3; 
6 MU/m2, day 1, 
week 4; 9 MU/m2, 
days 1, 3 and 5, 
weeks 5-8) and  
5-FU 750 mg/m2, 
i.v. bolus, day 1, 
weeks 5-8 
Arm B – 
observation 
High risk patients 
defined as: 
 T3b/c or T4 
 any pT, pN1 
or pN2 or 
 any pT with 
positive 
microscopic 
margins or 
microscopic 
vascular 
invasion 
 DFS at 3 years was 
50% with obser-
vation and 61% 
with treatment (HR 
= 0.84, 95% CI = 
0.63-1.12, p=0.233) 
 OS at 5 years was 
63% with obser-
vation and 70% 
with treatment (HR 
= 0.87, 95% CI = 
0.61-1.23, p=0.428) 
 35% of pts did not complete 
the treatment, primarily 
due to toxicity (92% of 
patients experienced ≥ 
grade 2 AEs, 41% ≥ grade 3 
AEs) 
25 
*Reference numbers refer to the reference list in the main text of the Review. Pts, patients; RFS, 
relapse-free (or recurrence-free) survival; t.i.w., three times in a week; o.d., once a day; b.i.d., twice a 
day; CSS, cancer-specific survival; PFI, progression-free interval; n.s., not significant; DTCH, delayed type 
cutaneous hypersensitivity; QoL, quality of life; i.v., intravenous; HR, hazard ratio; CI, confidence 
interval; OS, overall survival; IFN, Interferon; s.c., subcutaneous; IL-2, Interleukin-2; AEs, adverse 
events. 
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Supplementary table 2 | Unpublished phase III trials of targeted agents for the 
adjuvant treatment of resected RCC 
 
*Reference numbers refer to the reference list in the main text of the Review. ECOG, Eastern 
Cooperative Oncology Group; RFS, relapse-free survival; DFS, disease-free survival. 
  
Trial Inclusion criteria Treatment Patients 
(n) 
Primary 
end 
point 
Status Refs* 
ATLAS 
(NCT01599754) 
 Preponderant clear cell histology 
(defined as >50%) 
 pT2, N0 or Nx, M0 and ECOG PS 0-1 
 pT3, N0 or Nx, M0 and ECOG PS 0-1 
 pT4, N0 or Nx, M0 and ECOG PS 0-1 
Any pT, N1, M0 and ECOG PS 0-1 
Axitinib 5 mg twice a 
day for 3 years versus 
placebo (same 
schedule) 
722 RFS Completed 
Did not 
meet 
primary 
end point 
45 
EVEREST 
(NCT01120249) 
 Clear cell or non-clear cell RCC 
 Considered pathologically either 
intermediate high-risk or very high-risk 
 Radical or partial nephrectomy 
 Removal of all clinically positive nodes 
 Patients with microvascular invasion of 
the renal vein of any grade or stage (as 
long as M0) allowed 
Everolimus 10 mg once 
a day on days 1-42 
repeated every 6 weeks 
for 9 courses versus 
placebo (same 
schedule) 
1,545 RFS Active but 
not 
recruiting 
Results 
pending 
52 
SORCE 
(NCT00492258) 
 Clear cell or non-clear cell histology 
 Intermediate or high-risk disease 
(Leibovich score 3–11) 
Sorafenib 400 mg twice 
a day for 1 year 
followed by oral 
placebo twice a day for 
2 years versus oral 
sorafenib twice a day 
for 3 years versus oral 
placebo twice a day for 
3 years 
1,656 DFS Completed 
Results 
pending 
46 
 36 
Supplementary table 3 | Ongoing trials with immune checkpoint inhibitors in the 
setting of the adjuvant treatment of resected RCC 
 
Trial Drug (target) Patients 
(n) 
Histology 
allowed 
Duration of 
adjuvant Tx 
Risk inclusion 
criteria 
Treatment 
arms 
Primary 
end point 
Refs* 
PROSPER 
(NCT03055013) 
Nivolumab (anti-
PD-1) 
766 All (but cap 
for nccRCC 
at 15%) 
10 months (1 
month of 
neo-adjuvant 
Tx, then 9 
months of 
adjuvant Tx) 
 > cT2a, N0, 
M0 
 cTany, N1, 
M0  
(metastasectomy 
excluded) 
Neoadjuvant 
nivolumab 240 
mg Q2W x 2 
[resect] + 
adjuvant 
nivolumab 240 
mg Q2W x 6 
and 480 mg 
Q4W x 6 versus 
observation 
>13% 
improveme
nt in RFS 
59 
Immotion 010 
(NCT03024996) 
Atezolizumab 
(anti-PD-L1) 
664 Clear cell 
component 
or any 
subtype with 
sarcomatoid 
component 
required 
12 months  
(16 cycles) 
 pT2, Gr4 or 
 pT3a, Gr3-4 
or 
 pT3b-T4, 
Grany or 
 N1, pTany, 
Grany or 
 M1 NED 
atezolizumab 
1200mg Q3W x 
16 versus 
placebo Q3W x 
16 
DFS 60 
Keynote-564 
(NCT03142334) 
Pembrolizumab 
(anti-PD-1) 
1000 Clear cell or 
clear cell 
component 
with or 
without 
sarcomatoid 
features 
12 months 
(17 cycles) 
 pT2, Gr 4 
(sarcomatoi
d), N0 or 
 pT3, Gr 3-4, 
N0 or 
 pT4, Grany, 
N0 or 
 N1, pTany, 
Grany or 
 M1 NED 
Pembrolizumab 
200 mg Q3W x 
17 versus 
placebo Q3W 
x17 (12 months) 
DFS 61 
RAMPART 
(NCT03288532) 
Durvalumab 
(anti-PD-L1) 
and 
Tremelimumab 
(anti-CTLA4) 
1750 All except 
pure 
oncocytoma, 
collecting 
duct, 
medullary 
and 
transitional 
cell cancer 
12 months 
(max 13 
cycles) 
At the start of 
recruitment 
patients with 
Leibovich score 
3-11 will be 
eligible for 
randomisation. 
Recruitment of 
intermediate risk 
patients 
(Leibovich score 
3-5) after 3 years 
or when 
intermediate risk 
patients 
contribute 25% 
of the total 
accrual target, 
whichever is 
earlier. 
Recruitment of 
patients with 
Leibovich Score 
6-11 will 
continue until the 
accrual target is 
reached 
Active 
monitoring for 1 
year versus 
durvalumab 
1500 mg 4 
weekly for 1 
year (13 cycles 
maximum) 
versus 
durvalumab (as 
above) + 
tremelimumab 
(75 mg) on day 
1 and week 4 
visits (i.e. 2 
cycles) 
DFS and 
OS 
62 
CheckMate 914, 
NCT03138512 
Ipilimumab 
(anti-CTLA4) 
and Nivolumab 
(anti-PD1) 
800 Predominant 
histology, 
including 
sarcomatoid 
24 weeks  pT2a, G3 or 
G4, N0 or 
 pT2b, Gany, 
N0 
Nivolumab plus 
ipilimumab  
DFS 63 
 37 
 
*Reference numbers refer to the reference list in the main text of the Review. PD-1 – Programmed 
death-1; ECOG – Eastern Cooperative Oncology Group; nccRCC – non clear cell Renal Cell Carcinoma; 
Tx – treatment; Q2W – every two weeks; Q4W – every four weeks; RFS – relapse-free survival; PD-L1 – 
Programmed death ligand-1; SUO CTC – Society of Urological Oncology Clinical Trials Consortium; Gr – 
grade; NED – without evidence of residual disease; Q3W – every three weeks; DFS – disease-free 
survival; CTLA-4 – Cytotoxic T-Lymphocyte Antigen 4; UCL – University College London; OS – overall 
survival. 
 
features  or pT3, 
Gany, N0 or 
pT4, Gany, 
N0 or 
 pTany, 
Gany, N1 
